Combination Therapy in Pulmonary Arterial Hypertension: Single Centre Long-term Experience

Creative Commons License

Tacoy G., Cengel A., Alsancak Y., Unlu S., Turkoglu S.

WEST INDIAN MEDICAL JOURNAL, cilt.65, sa.1, ss.46-51, 2016 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 65 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.7727/wimj.2014.148
  • Dergi Adı: WEST INDIAN MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.46-51
  • Anahtar Kelimeler: Combination therapy, hypertension, pulmonary artery, BOSENTAN THERAPY, INHALED ILOPROST, RIGHT VENTRICLE, DOUBLE-BLIND, RIGHT-HEART, EPOPROSTENOL, SILDENAFIL, SURVIVAL, REGISTRY, TRIAL
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vascular bed and causes right heart failure and death. Combination therapy which targets three different pathways is necessary due to the progressive nature of the disease. In patients with PAH, there are two approaches in combination therapy: "first-line up-front" and "sequential add-on" treatment. In "firstline up-front" treatment, patients receive double or triple drug therapy from the start. In the "sequential add-on" approach, a single drug is initially started and then according to the patient's requirements, a second or third drug is added. There is insufficient evidence about the efficiency and safety of treatment approaches. In this study, we aimed to evaluate the treatment approach in patients with PAH at a tertiary centre.